Recent clinical observations suggest that early combination therapy with ribavirin and supportive care including aggressive fluid management significantly improves survival rates. A meta-analysis of recent cases shows mortality reduction from 38% to approximately 25% when treatment is initiated within the first week of symptom onset. Researchers emphasize the critical importance of rapid diagnosis and transport to centers equipped to provide ECMO support.